Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT510A vs ranibizumab in wet AMD
CTR20221725Phase 3Terminated
- Sponsor
- Sinocelltech Group Limited
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCT510A in exudative macular degeneration, sponsored by Sinocelltech Group Limited. Started Jul 2022; status: terminated.
02
Drugs
SCT510A
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20221725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221725.